Gufic Biosciences Limited (509079) Fair Value & Analysis
Healthcare · IN · Market cap ₹7.0B
Fair value as of: Aug 15, 2026
From 26 valuation models · updated today
Share price +6.3% over the past month.
Below-average quality, and screening another 57% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹246.10). The favourable scenario is already priced in.
- The model range is unusually wide (₹81.58 to ₹246.10). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
60‑month range ₹108.35 – ₹486.87 · fair‑value band ₹81.58 – ₹246.10 · the ₹421.20 price screens above the ₹182.30 fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
Gufic Biosciences Limited (509079) currently trades at ₹421.20, while our model-based Fair Value estimate is ₹182.30, implying the stock looks roughly 56.7% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Gufic Biosciences Limited generated revenue of ₹3.5B at a net margin of 6.9%. Revenue grew 42.5% year over year. It earns a return on equity of 25.2%. The stock trades on a trailing P/E of 77.1 (as of Aug 15, 2026). Fundamentals as of Aug 15, 2026
Our scenario range runs from ₹81.58 (bear case) to ₹246.10 (bull case); at ₹421.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 6% below its 52-week high and 57% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside, at -57%, 509079 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹220.60) versus Dividend Discount (₹1.95). Highest evidence: Growth DCF (80).
Notify me when 509079 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anaesthetics, and immuno suppressants, as well as intermediates for antifungals.
Full company description
Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anaesthetics, and immuno suppressants, as well as intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products. The company was founded in 1970 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Gufic Biosciences Limited reported revenue of ₹8.2B in FY2025 versus ₹4.9B in FY2021, a compound +13.9%/yr. Reported net income was ₹696M in FY2025, compounding +12.0%/yr from FY2021.
509079 screens 57% overvalued. Compare with Indoco Remedies Limited →
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹222.50 | ₹96.79 | -56% |
| Anuh Pharma Limited 506260 | ₹77.18 | ₹51.89 | -33% |
| Medicamen Biotech Limited 531146 | ₹236.75 | ₹95.98 | -59% |
| Coral Laboratories Limited 524506 | ₹579.05 | ₹779.23 | +35% |
| Gennex Laboratories Limited 531739 | ₹9.00 | ₹27.82 | +209% |
| Lactose (India) Limited 524202 | ₹106.25 | ₹130.91 | +23% |
| Beryl Drugs Limited 524606 | ₹23.18 | ₹14.44 | -38% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
Compare Gufic Biosciences Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gufic Biosciences Limited (509079) overvalued or undervalued?
What is the fair value of 509079?
What is the quality score of 509079?
What is the revenue of Gufic Biosciences Limited (509079)?
What is the net profit margin of 509079?
Does Gufic Biosciences Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Gufic Biosciences Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.